1. BCL-2 inhibition in haematological malignancies: Clinical application and complications
   Dominic J. Fowler-Shorten et al, 2024, Blood Reviews CrossRef
2. Anticancer Agents Based on Vulnerable Components in a Signalling Pathway
   Ankur Vaidya et al, 2020, Mini-Reviews in Medicinal Chemistry CrossRef
3. Conjugation of Ginsenoside with Dietary Amino Acids: A Promising Strategy To Suppress Cell Proliferation and Induce Apoptosis in Activated Hepatic Stellate Cells
   Lu Ma et al, 2019, Journal of Agricultural and Food Chemistry CrossRef
4. Bcl‐2/Bcl‐xl inhibitor APG‐1252‐M1 is a promising therapeutic strategy for gastric carcinoma
   Hanjie Yi et al, 2020, Cancer Medicine CrossRef
5. Calreticulin regulated intrinsic apoptosis through mitochondria-dependent and independent pathways mediated by ER stress in arsenite exposed HT-22 cells
   Xiaotong Wang et al, 2020, Chemosphere CrossRef
6. B‐cell lymphoma‐2 family proteins in the crosshairs: Small molecule inhibitors and activators for cancer therapy
   Qineng Gong et al, 2024, Medicinal Research Reviews CrossRef
7. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer
   Yu Bai et al, 2019, Current Topics in Medicinal Chemistry CrossRef
8. Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐xL Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches
   Arvind Negi et al, 2022, ChemBioChem CrossRef
9. Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers
   Jiaxuan Xu et al, 2023, Cancers CrossRef
10. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway
    Fan Luo et al, 2021, Cell Death & Disease CrossRef
11. Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis
    Weilong Yao et al, 2022, Neoplasia CrossRef
12. Therapeutic potential of the novel Bcl‐2/Bcl‐XL dual inhibitor, APG1252, alone or in combination against non‐small cell lung cancer
    Luxi Qian et al, 2022, Molecular Carcinogenesis CrossRef
13. Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer
    Simona D’Aguanno et al, 2020, Cells CrossRef
14. The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy
    Alakananda Basu, 2022, Pharmacology & Therapeutics CrossRef
15. Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model
    Hirofumi Tsuzuki et al, 2022, Oncotarget CrossRef
16. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
    Xin Xie et al, 2023, Signal Transduction and Targeted Therapy CrossRef
17. Rational design, synthesis and biological evaluation of triphenylphosphonium-ginsenoside conjugates as mitochondria-targeting anti-cancer agents
    Lu Ma et al, 2020, Bioorganic Chemistry CrossRef
18. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy
    Vasanti Suvarna et al, 2019, European Journal of Pharmacology CrossRef
19. A new niclosamide derivatives‐B17 can inhibit urological cancers growth through apoptosis‐related pathway
    Chia‐Lun Wu et al, 2018, Cancer Medicine CrossRef
20. Programmed cell death, redox imbalance, and cancer therapeutics
    Xiaofeng Dai et al, 2021, Apoptosis CrossRef